Physician profile
Katherine A Roberts
NPI 1437348851
$4,811.52
in general payments reported to CMS, 2019-2025
39 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $217 · 2021: $36.33 · 2022: $471 · 2023: $955 · 2024: $952 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $650.03 | 2019-2025 | Korlym |
| Amgen INC. | $633.60 | 2019-2025 | Tepezza, Repatha, Evenity |
| Mannkind Corporation | $357.49 | 2024-2025 | |
| Lilly USA, LLC | $310.88 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Abbvie INC. | $294.68 | 2019-2024 | Synthroid |
| Novo Nordisk INC | $291.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $251.58 | 2023-2025 | Omnipod |
| Horizon Therapeutics Plc | $208.01 | 2022-2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $193.63 | 2019-2024 | Farxiga, Lokelma |
| Radius Health, INC. | $184.06 | 2019-2025 | Tymlos |
| Acella Pharmaceuticals, LLC | $123.86 | 2023-2025 | NP Thyroid 60 |
| Shire North American Group INC | $116.39 | 2019 | |
| Kyowa Kirin, INC. | $107.78 | 2022-2025 | Crysvita |
| Amneal Pharmaceuticals LLC | $106.17 | 2019-2024 | Unithroid |
| Xeris Pharmaceuticals, INC. | $96.50 | 2022-2025 | Gvoke Hypopen, Recorlev |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $87.32 | 2023 | Cabometyx |
| Recordati_rare_diseases_inc. | $84.85 | 2023-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $69.05 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Halozyme INC | $62.50 | 2023 | |
| Cequr Corporation | $60.51 | 2024 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $60.14 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.45 | 2022-2025 | Jardiance |
| Medtronic, INC. | $53.56 | 2022-2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $46.00 | 2019-2024 | Strensiq |
| Ionis Pharmaceuticals, INC. | $27.17 | 2025 | Tryngolza |
| Abbott Laboratories | $24.02 | 2024 | Proclaim |
| Beta Bionics, INC. | $23.49 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Averitas Pharma INC. | $20.81 | 2023 | Qutenza |
| Tandem Diabetes Care, INC. | $18.57 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $18.46 | 2020 | |
| Sequel Med Tech, LLC | $17.62 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $16.95 | 2025 | Yorvipath |
| Azurity Pharmaceuticals, INC. | $16.63 | 2023 | Adthyza |
| Takeda Pharmaceuticals U.S.A., INC. | $14.54 | 2020 | |
| Senseonics, Incorporated | $14.00 | 2019 | |
| Dexcom, INC. | $13.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.20 | 2019 | |
| Gilead Sciences, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.